 |
| |
|
| News |
|
|
|
|
| |
| |
 |
| |
|
| Transgene has filed 2 patents for its Liver and Breast Cancer drug technologies based on its proprietary RNAi platform. Both patents follow excellent results in their respective animal studies. Liver cancer is the 3rd most common cause of cancer mortality, and breast cancer is the most common cancer in women. The company is expecting to file more patents on some of its other technologies shortly. |
|
|
|
A new drug for treating Breast Cancer, developed using Transgene’s proprietary RNAi technology platform, has demonstrated exciting results in its latest animal studies. This drug is specifically designed not only to treat primary Breast Cancer but also to fight against potential metastatic tumours. Worldwide, Breast Cancer is the most common cancer in women, representing 16% of all female cancers, and causes well over 500,000 deaths annually. |
|
|
|
| A novel drug for Liver Cancer developed by Transgene Biotek’s scientists has demonstrated excellent efficacy in the latest animal studies, which corroborates earlier data gathered from in-vitro studies. Transgene has employed its RNAi platform, which utilizes a novel gene silencing technology, to develop this drug, which has demonstrated remarkable regression of the tumours in tests. Liver Cancer is the fifth most common cancer in the world, and the third most common cause of cancer mortality. |
|
|
|
| Transgene Biotek has crossed a significant milestone in demonstrating the efficacy of a therapeutic AIDS vaccine developed by its scientists. This vaccine prevents the progression of AIDS in HIV infected persons, and almost reverses the AIDS process by enabling reactivation of the body's natural immunity, which otherwise gets depleted and often results in death. The AIDS vaccine is the first product to come out of a novel platform that Transgene has built for drugs against auto-immune diseases. Other drugs currently under development on this platform target Rheumatoid Arthritis and Multiple Sclerosis, and the platform can be extended against other autoimmune diseases such as Crohn’s Disease etc. |
|
|
|
|
The second announcement of Dr Reddy’s is a tie-up with Indian biotechnology company Transgene Biotek to manufacture and market Orlistat, an obesity management drug. The market size for obesity management drugs accounts for $2 billion worldwide with pancreatic lipase inhibitors such as Orlistat contributing to about half of this. |
|
|
|
| Transgene Biotek (TBL) has entered into a Licensing and Technology Transfer Agreement with Dr. Reddy’s Labs (DRL) for the out-licensing of a technology for the manufacture of Orlistat, which was developed exclusively by TBL. This unique technology will be licensed by TBL and manufactured and marketed by Dr. Reddy’s globally. The agreement should lead to substantial revenues being generated for TBL and DRL for several years to come, and to a many fold increase in TBL’s bottomline. The market for Orlistat is estimated to be around US $500 million per year. |
|
|
|
| |
|
| |
| |
| |
|
|
|
|
|
|
